10.25376/hra.7845242.v1 Jason Stubbs Jason Stubbs Margaret Stedman Margaret Stedman Sai Liu Sai Liu Jin Long Jin Long Yoko Franchetti Yoko Franchetti Raymond West III Raymond West III Alex Prokopienko Alex Prokopienko Jonathan Mahnken Jonathan Mahnken Glenn Chertow Glenn Chertow Tom Nolin Tom Nolin Stubbs et al - TMAO and CV Outcomes in EVOLVE_CJASN.pdf Health Research Alliance 2019 cardiovascular disease chronic kidney disease gut microbiome end-stage kidney disease Cardiology (incl. Cardiovascular Diseases) Nephrology and Urology 2019-03-14 17:33:56 Journal contribution https://hra.figshare.com/articles/journal_contribution/Stubbs_et_al_-_TMAO_and_CV_Outcomes_in_EVOLVE_CJASN_pdf/7845242 The data demonstrates that baseline levels of TMAO, a circulating compound derived from byproducts of intestinal bacteria, do not predict cardiovascular endpoints in patients with end-stage kidney disease.